1. Vaccarella S, Dal Maso L, Laversanne M, Bray F, Plummer M, Franceschi S: The Impact of Diagnostic Changes on the Rise in Thyroid Cancer Incidence: A Population-Based Study in Selected High-Resource Countries.Thyroid 2015, 25:1127-1136.
2. Rahib L, Smith B, Aizenberg R, Rosenzweig A, Fleshman J, Matrisian L: Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.Cancer research 2014, 74:2913-2921.
3. Chowdhury S, Veyhl J, Jessa F, Polyakova O, Alenzi A, MacMillan C, Ralhan R, Walfish P: Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.Oncotarget 2016, 7:32318-32328.
4. Schreiber R, Old L, Smyth M: Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.Science (New York, NY) 2011, 331:1565-1570.
5. Grivennikov S, Greten F, Karin M: Immunity, inflammation, and cancer.Cell 2010, 140:883-899.
6. Galdiero MR, Varricchi G, Marone G: The immune network in thyroid cancer.Oncoimmunology 2016, 5:e1168556.
7. Chen DS, Mellman I: Oncology meets immunology: the cancer-immunity cycle.Immunity 2013, 39:1-10.
8. Bastman J, Serracino H, Zhu Y, Koenig M, Mateescu V, Sams S, Davies K, Raeburn C, McIntyre R, Haugen B, French J: Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer.The Journal of clinical endocrinology and metabolism 2016, 101:2863-2873.
9. Mehnert J, Varga A, Brose M, Aggarwal R, Lin C, Prawira A, de Braud F, Tamura K, Doi T, Piha-Paul S, et al: Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.BMC cancer 2019, 19:196.
10. Cabanillas M, Habra M: Lenvatinib: Role in thyroid cancer and other solid tumors.Cancer treatment reviews 2016, 42:47-55.
11. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, et al: Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.Lancet 2014, 384:319-328.
12. Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, Barrette TR, Prensner JR, Evans JR, Zhao S, et al: The landscape of long noncoding RNAs in the human transcriptome.Nat Genet 2015, 47:199-208.
13. Sahu A, Singhal U, Chinnaiyan A: Long noncoding RNAs in cancer: from function to translation.Trends in cancer 2015, 1:93-109.
14. Fang Y, Fullwood M: Roles, Functions, and Mechanisms of Long Non-coding RNAs in Cancer.Genomics, proteomics & bioinformatics 2016, 14:42-54.
15. Mercer T, Dinger M, Mattick J: Long non-coding RNAs: insights into functions.Nature reviews Genetics 2009, 10:155-159.
16. Chen Y, Satpathy A, Chang H: Gene regulation in the immune system by long noncoding RNAs.Nature immunology 2017, 18:962-972.
17. Bhan A, Soleimani M, Mandal SS: Long Noncoding RNA and Cancer: A New Paradigm.Cancer Res 2017, 77:3965-3981.
18. Feng J, Zhou Q, Yi H, Ma S, Li D, Xu Y, Wang J, Yin S: A novel lncRNA n384546 promotes thyroid papillary cancer progression and metastasis by acting as a competing endogenous RNA of miR-145-5p to regulate AKT3.Cell death & disease 2019, 10:433.
19. Huang Z, Xiao C, Zhang F, Zhou Z, Yu L, Ye C, Huang W, Li N: A Novel Framework to Predict Breast Cancer Prognosis Using Immune-Associated LncRNAs.Frontiers in genetics 2020, 11:634195.
20. Xu Q, Wang Y, Huang W: Identification of immune-related lncRNA signature for predicting immune checkpoint blockade and prognosis in hepatocellular carcinoma.International immunopharmacology 2021, 92:107333.
21. Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W, Smyth G: limma powers differential expression analyses for RNA-sequencing and microarray studies.Nucleic acids research 2015, 43:e47.
22. Friedman J, Hastie T, Tibshirani R: Regularization Paths for Generalized Linear Models via Coordinate Descent.J Stat Softw 2010, 33:1-22.
23. Fagin JA, Wells SA, Jr.: Biologic and Clinical Perspectives on Thyroid Cancer.N Engl J Med 2016, 375:2307.
24. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, et al: 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.Thyroid 2016, 26:1-133.
25. Kentwell J, Gundara J, Sidhu S: Noncoding RNAs in endocrine malignancy.The oncologist 2014, 19:483-491.
26. Liu J, Dong H, Yang Y, Qian Y, Liu J, Li Z, Guan H, Chen Z, Li C, Zhang K, et al: Upregulation of long noncoding RNA MALAT1 in papillary thyroid cancer and its diagnostic value.Future Oncol 2018, 14:3015-3022.
27. Subhash S, Kalmbach N, Wegner F, Petri S, Glomb T, Dittrich-Breiholz O, Huang C, Bali KK, Kunz WS, Samii A, et al: Transcriptome-wide Profiling of Cerebral Cavernous Malformations Patients Reveal Important Long noncoding RNA molecular signatures.Sci Rep 2019, 9:18203.
28. Liu J, Wang Y, Chu Y, Xu R, Zhang D, Wang X: Identification of a TLR-Induced Four-lncRNA Signature as a Novel Prognostic Biomarker in Esophageal Carcinoma.Front Cell Dev Biol 2020, 8:649.
29. Wu L, Wen Z, Song Y, Wang L: A novel autophagy-related lncRNA survival model for lung adenocarcinoma.J Cell Mol Med 2021.
30. Guo K, Chen L, Wang Y, Qian K, Zheng X, Sun W, Sun T, Wu Y, Wang Z: Long noncoding RNA RP11-547D24.1 regulates proliferation and migration in papillary thyroid carcinoma: Identification and validation of a novel long noncoding RNA through integrated analysis of TCGA database.Cancer Med 2019, 8:3105-3119.
31. Zhu X, Tian X, Yu C, Shen C, Yan T, Hong J, Wang Z, Fang JY, Chen H: A long non-coding RNA signature to improve prognosis prediction of gastric cancer.Mol Cancer 2016, 15:60.
32. Gu J, Zhang X, Miao R, Xiang X, Fu Y, Zhang J, Liu C, Qu K: Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.World journal of gastroenterology 2019, 25:220-232.
33. Peng PL, Zhou XY, Yi GD, Chen PF, Wang F, Dong WG: Identification of a novel gene pairs signature in the prognosis of gastric cancer.Cancer Med 2018, 7:344-350.
34. Li B, Cui Y, Diehn M, Li R: Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.JAMA Oncol 2017, 3:1529-1537.
35. Zhang Y, Zhang Z: The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications.Cellular & molecular immunology 2020, 17:807-821.
36. Denaro N, Merlano M, Lo Nigro C: Long noncoding RNAs as regulators of cancer immunity.Molecular oncology 2019, 13:61-73.
37. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS: TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells.Cancer Res 2017, 77:e108-e110.
38. Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, Li B, Liu XS: TIMER2.0 for analysis of tumor-infiltrating immune cells.Nucleic Acids Res 2020, 48:W509-w514.
39. Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA: Profiling Tumor Infiltrating Immune Cells with CIBERSORT.Methods Mol Biol 2018, 1711:243-259.
40. Aran D: Cell-Type Enrichment Analysis of Bulk Transcriptomes Using xCell.Methods Mol Biol 2020, 2120:263-276.
41. Finotello F, Mayer C, Plattner C, Laschober G, Rieder D, Hackl H, Krogsdam A, Loncova Z, Posch W, Wilflingseder D, et al: Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data.Genome Med 2019, 11:34.
42. Dienstmann R, Villacampa G, Sveen A, Mason MJ, Niedzwiecki D, Nesbakken A, Moreno V, Warren RS, Lothe RA, Guinney J: Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.Ann Oncol 2019, 30:1622-1629.
43. Racle J, de Jonge K, Baumgaertner P, Speiser DE, Gfeller D: Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data.Elife 2017, 6.
44. Tamminga M, Hiltermann TJN, Schuuring E, Timens W, Fehrmann RS, Groen HJ: Immune microenvironment composition in non-small cell lung cancer and its association with survival.Clin Transl Immunology 2020, 9:e1142.
45. Yu H, Huang X, Liu X, Jin H, Zhang G, Zhang Q, Yu J: Regulatory T cells and plasmacytoid dendritic cells contribute to the immune escape of papillary thyroid cancer coexisting with multinodular non-toxic goiter.Endocrine 2013, 44:172-181.
46. Angell TE, Lechner MG, Jang JK, Correa AJ, LoPresti JS, Epstein AL: BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.Thyroid 2014, 24:1385-1393.
47. Hilly O, Koren R, Raz R, Rath-Wolfson L, Mizrachi A, Hamzany Y, Bachar G, Shpitzer T: The role of s100-positive dendritic cells in the prognosis of papillary thyroid carcinoma.Am J Clin Pathol 2013, 139:87-92.
48. Mao M, Huang R, Zheng J, Liang H, Huang W, Liu J, Li J: OGDHL closely associates with tumor microenvironment and can serve as a prognostic biomarker for papillary thyroid cancer.Cancer medicine 2021, 10:728-736.
49. Liu Y, Yun X, Gao M, Yu Y, Li X: Analysis of regulatory T cells frequency in peripheral blood and tumor tissues in papillary thyroid carcinoma with and without Hashimoto's thyroiditis.Clin Transl Oncol 2015, 17:274-280.
50. French JD, Weber ZJ, Fretwell DL, Said S, Klopper JP, Haugen BR: Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer.J Clin Endocrinol Metab 2010, 95:2325-2333.
51. Zhou C, Duan D, Liu S: Predictive Value of a Prognostic Model Based on Lymphocyte-to-Monocyte Ratio Before Radioiodine Therapy for Recurrence of Papillary Thyroid Carcinoma.Technol Cancer Res Treat 2021, 20:15330338211027910.
52. Cunha L, Marcello M, Morari E, Nonogaki S, Conte F, Gerhard R, Soares F, Vassallo J, Ward L: Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation.Endocrine-related cancer 2013, 20:103-110.
53. Shi R, Qu N, Luo T, Xiang J, Liao T, Sun G, Wang Y, Wang Y, Huang C, Ji Q: Programmed Death-Ligand 1 Expression in Papillary Thyroid Cancer and Its Correlation with Clinicopathologic Factors and Recurrence.Thyroid : official journal of the American Thyroid Association 2017, 27:537-545.